Bio

Anita Mohan MBBS PhD MBA is a Clinical Assistant Professor in the Division of Plastic and Reconstructive Surgery. Dr Mohan graduated medical school from Imperial College London together with a bachelors with honors in Management (BSc). After completing core surgery residency training in London in the United Kingdom, she completed a clinical fellowship in plastic surgery, hand surgery and burns in Cape Town, South Africa. This was followed by plastic surgery training in Cambridge, United Kingdom. During her plastic surgery training program, Dr Mohan was awarded the Royal College of Surgeons (England) Blond McIndoe research scholarship which she used to pursue a post-doctoral research fellowship at the Mayo Clinic, Rochester Minnesota. In this time Dr Mohan completed her PhD from the University of Cambridge (U.K.) on the study of perforator anatomy and physiology of the microcirculation in breast reconstruction, for which she received the Royal College of Surgeons of England Aris and Gale Lectureship. Dr Mohan also worked in the lab at Mayo Clinic in the study of nerve regeneration in facial allotransplantation. Dr Mohan then went on to complete an integrated plastic surgery residency at the Mayo Clinic, Rochester Minnesota. Dr Mohan also completed her Masters in Business Administration (MBA) from the University of Minnesota during her residency training. Dr Mohan completed advanced training in reconstructive microsurgery at Stanford University and studied medical innovation in the Stanford Biodesign program.

Dr Mohan has a joint appointment at the Veteran’s Affairs Hospital in Palo Alto and Stanford University campus. Dr Mohan’s specializes in general reconstructive surgery, microsurgery and super-microsurgery techniques. Dr Mohan currently performs a broad scope of plastic surgery procedures, gender affirming top surgery with nipple neurotization, breast and abdominal procedures following massive weight loss, abdominal wall reconstruction, microsurgery reconstruction following cancer and trauma, lymphedema/lipedema and skin cancer surgery.

Dr Mohan’s research interests include the study of microcirculation and lymphedema research, clinical outcomes projects and simulation training.

Clinical Focus

  • Plastic Surgery

Academic Appointments

Administrative Appointments

  • Instructor in Surgery, Mayo Clinic, Rochester, MN (2022 - 2022)
  • Clinical Instructor, Stanford University (2022 - 2023)
  • Clinical Assistant Professor, Stanford School of Medicine (2023 - Present)

Honors & Awards

  • Maki Graduate Scholarship, Labovitz School of Business and Economics, University of Minnesota (2021)
  • Resident Scholarship, Aesthetic Society Education and Research Foundation (ASERF) (2021)
  • Maki Graduate Scholarship, Labovitz School of Business and Economics, University of 2020 Minnesota (2020)
  • Poster of Distinction, Balfour Surgery Research Symposium, Rochester, MN (2019)
  • National Endowment in Plastic Surgery Award, Plastic Surgery Foundation (PSF), USA (2019)
  • Finalist Beahrs Innovation Summit Shark Tank, Department of Surgery, Mayo Clinic, Rochester, MN (2019)
  • Arris and Gale Lectureship, Royal College of Surgeons of England, London, UK (2018)
  • Second place, Best Oral Presentation, Minnesota Surgical Society (MSS), Rochester MN (2018)
  • Top Paper in Translational Research, Mayo Clinic Young Investigators Research Symposium, Mayo Clinic. (2018)
  • Poster of Distinction, Annual American College of Surgeons Surgical Simulation Summit, Chicago,IL, USA (2018)
  • American Society for Reconstructive Transplantation (ASRT) Travelers Scholarship, American Society for Reconstructive Transplantation (ASRT) (2018)
  • Welton Foundation award,, Welton Foundation, London, UK (2015)
  • Gibson Prize, Best Paper Award, Society of Academic Research Surgery (SARS), Royal College of Surgeons of England (2016)
  • Research Fellowship, London, UK, Blond Royal College of Surgeons of England (2015)
  • Travelling Bursary for Presentation Overseas, London,UK, British Association of Plastic, Reconstructive and Aesthetic Surgeons (2015)
  • Novadaq Technologies (Vancouver CA) Travelling Bursary, World Society of Reconstructive Microsurgery (2015)
  • Best Resident Paper, American Society of Reconstructive Microsurgery (2015)
  • Best Paper Award, Chang Gung Mayo Clinic Symposium in Reconstructive Surgery Taiwan (2014)
  • Commendation for Outstanding Presentation, Red Cross War Memorial Children’s Hospital, Cape Town, S. Africa (2011)

Boards, Advisory Committees, Professional Organizations

  • Reviewer, Aesthetic Surgery Journal, European Journal of Plastic Surgery, PLoS open access Frontiers in Plastic Surgery, Annals of Plastic Surg (2014 - Present)
  • Sub-Committee Member, American Society of Plastic Surgery Research (2020 - Present)
  • Associate Editor, Frontiers in Surgery Journal (2022 - Present)
  • Sub-Committee Member, American Society of Plastic Surgery Clinical Research (2020 - Present)
  • Committee member, Reconstructive Surgery Trials Network, UK (2015 - 2017)
  • Assistant Editor, Breast Section of Plastic Surgery Education Network Editorial Committee (2014 - 2015)

Professional Education

  • Microsurgery Clinical Instructor, Stanford Division of Plastic and Reconstructive Surgery, Stanford, CA (2023)
  • Residency: Mayo Clinic Plastic Surgery Integrated Program (2022) MN United States of America
  • Medical Education: Imperial College, School of Medicine (2006) UK

Contact

  • Academic
    atmohan@stanford.edu
    University - Academic staff Department: Surgery - Plastic and Reconstructive Surgery Position: Clinical Assistant Professor
  • Clinical (Primary)  Stanford Plastic Surgery Clinic 1000 Welch Rd MC 5348 Palo Alto, CA 94304 (650) 725-5223 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5715

Links

2023-24 Courses

Stanford Advisees

All Publications

  • Breast reconstruction after mastectomy in patients with obesity: a narrative review. Annals of translational medicine Cevallos, P., Berry, C., Lipman, K. J., Kubiak, C. A., Mohan, A. T., Ayyala, H. S., Manrique, O. J., Nazerali, R. 2023; 11 (12): 413

    Abstract

    Breast reconstruction in patients with obesity presents numerous challenges, both in terms of surgical technique and post-operative complication management. As breast reconstruction techniques continue to evolve, the armamentarium of reconstructive options for patients with obesity has vastly expanded. Options now include immediate or delayed, implant-based, autologous, or hybrid reconstruction. Determining the optimal breast reconstruction in this complex population requires nuanced and experienced decision-making.A literature search was conducted to identify studies assessing breast reconstruction considerations in patients with obesity. The search was performed on PubMed and was limited to English language studies published between 1990 and 2023. Primary studies, case reports, chart reviews, and qualitative studies were included. Additional articles were identified for inclusion based on a review of references, as well as a web-based search, to identify additional studies that were not captured with the primary search strategy.This narrative review article summarizes the current literature available to guide surgeons in breast reconstruction in patients with obesity.The advancements in oncologic surgery and breast reconstruction techniques have expanded available surgical options, including immediate or delayed implant-based, autologous, or hybrid breast reconstruction. Each approach has its unique advantages, disadvantages, and surgical considerations. Despite the challenges, patients with obesity can achieve favorable aesthetic outcomes through careful assessment of comorbidities and expectation management.

    View details for DOI 10.21037/atm-23-1599

    View details for PubMedID 38213816

    View details for PubMedCentralID PMC10777214

  • Radiation-Induced Morphea of the Breast Treated With Wide Local Excision and Abdominal Free Flap Breast Reconstruction. Eplasty Titan, A., Mohan, A. T., Tokuyama, M., Mirbegian, J., Bean, G. R., Lee, G. K. 2023; 23: e50

    Abstract

    Radiation-induced morphea (RIM) associated with breast cancer treatment is a rare and underdiagnosed skin complication of radiotherapy that can lead to severe and painful contractures, resulting in disfigurement, failure of reconstruction, and poor quality of life in patients. The condition may present on a spectrum of local or more generalized forms involving skin over the breast and anterior chest wall. This diagnosis must be differentiated from post-radiation fibrosis, infection, cancer recurrence, inflammatory breast cancer, and other inflammatory conditions as the clinical course and treatment approaches differ. Various noninvasive and topical agents have been used; however, many cases are refractory to treatment. Surgery has been less commonly described in the management of generalized RIM. This report describes a case of RIM in a patient with breast cancer who experienced simultaneous resolution of symptoms as well as successful breast reconstruction using autologous free-tissue transfer.

    View details for DOI 10.1097/01.SMJ.0000140866.97278.87

    View details for PubMedID 37664810

    View details for PubMedCentralID PMC10472431

  • Cell-Based Therapies in Vascularized Composite Allotransplantation Vyas, K. S., Mohan, A. T., Morrison, S. D., Tran, D. C., Mardini, S. THIEME MEDICAL PUBL INC. 2018: 642–50

    Abstract

     Dendritic cells (DCs) are bone marrow-derived, professional antigen-presenting cells with tolerogenic function. The ability of DCs to regulate alloantigen-specific T cell responses and to promote tolerance has aligned them ideally for a role in vascularized composite allotransplantation (VCA). In this study, we summarize the current evidence for DC therapies for tolerance induction to alleviate the requirement for chronic immunosuppression. A comprehensive and structured review of manuscripts published on VCA was performed using the MEDLINE and PubMed databases. All eligible studies published from the year 2000 to 2017 were included in the final results. Nineteen original preclinical and clinical studies that employed cell therapy for VCA were included in this review. In vivo DC therapy was found to direct the alloimmune response toward either transplant rejection or tolerance in VCA models. While injection of mature DCs rapidly increases T-cell activity in humans and promotes transplant rejection, the injection of immature DCs acts as an immunosuppressant and inhibits T-cell activity. In addition to immature DCs, mesenchymal stem cells were also found to have a positive effect on allotransplantation of solid organs and bone marrow via cytokine expression which decreases the alloreactive effector lymphocytes and increases CD4+/CD25+/FoxP3 Tregs. Despite the promising findings, the efficacy of cell-based therapies varies greatly across studies, partly due to different methods of cell isolation and purification techniques, source, route and timing of administration, and combination immunosuppressive therapy. Additional research is needed to evaluate the efficacy and safety of DC and other cell-based therapeutic measures in human allotransplant recipients. Future direction will focus on the development of novel methods to reduce immunosuppression and develop more individualized management, as well as the clinical application of basic research in the mechanisms of immunologic tolerance.

    View details for PubMedID 29945289